Cervical cancer brachytherapy amid the COVID-19 pandemic: A single
institutional case series
Abstract
Dose escalation to target volume during High Dose Rate brachytherapy was
effectively employed to treat locally advanced cervical cancer patients
who experienced prolongation of overall treatment time (OTT) due to the
COVID-19 pandemic. It was tried to achieve acceptable oncological
outcomesÙˆ while respecting the dose constraints of organs at risk.